The CF33, Vaxinia and Oncarlytics Deal, page-966

With SITC just around the corner it would be an understatement to say we need to some hard data and figures to restore faith in shareholders as well as proving the concept. At SITC Imugene will be presenting a Poster presentation in the form of a Clinical trial in progress. Theres been some speculation that there will be no data presented as Phase 1 is only a safety and tolerability but upon researching previous presentations it seem more likely that we will be seeing an interim read out of Vaxinia.

What also makes me think that we will be getting some data is that all of the authors that have contributed to the SITC poster are all the principal investigators of the hospitals where Vaxinia is being trialed. You’d assuming that they are contributing patient data from there respective locations.

https://www.sitcancer.org/2023/abstracts/abstract-titles-publications?SITC%202023%20Titles%20with%20URLs%5Bquery%5D=VaxxiniaIn the past there have been 3 ASX listed companies that have all presented at the SITC conference, these include:

VLA (2017)

IMM (2017,2018,2019,2020,2021,2022)

IMU (2022)

100% of all past abstracts and posters have included data read outs so I really am expecting something along these lines.

You can see all of the announcements from 2017-2022 and presentations at the below link for the above companies and the style that they have used to presnet these posters

https://hotcopper.com.au/search/8648382/?q=SITC&o=relevance&c%5Bvisible%5D=true&c%5Btitle_only%5D=1August 7th was the cut off date for normal abstract posters to be submitted so we could be looking at data from the first 3 cohorts plus cohort 1 of the combo arm.